Article
Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies.
Clinical pharmacology in drug development - 1 Jan 2021
Zhang Weijiang, Mathisen Michael, Goodman Grant R, Forbes Harper, Song Yuyao, Bertran Enric, Demidov Lev, Shin Sang Joon
Abstract excerpt
The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study. Patients with BRAFV600 mutation-positive metastatic malignancies received oral vemurafenib 960 mg twice daily on days 1 to 20 (period A) and oral vemurafenib 960 mg twice daily with oral itraconazole 200 mg once daily on days 21 to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.